Merck's Efinopegdutide Shows Positive Phase 2b Results for MASH with Fibrosis

Merck has announced positive results from its Phase 2b clinical trial evaluating efinopegdutide, a once-weekly, subcutaneous GLP-1/glucagon receptor co-agonist, in adults with metabolic dysfunction-associated steatohepatitis (MASH) and stage 2-3 fibrosis. The study met its primary efficacy endpoint, demonstrating a statistically significant greater proportion of participants achieved MASH resolution without worsening of fibrosis compared to placebo at 52 weeks. Meaningful improvements were also observed in liver fibrosis without worsening of steatohepatitis, a key secondary histologic endpoint. These findings were presented at The Liver Meeting® and published in The Lancet, indicating a potential new treatment option for this serious liver condition.